These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1083 related articles for article (PubMed ID: 29396129)

  • 21. Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin.
    Vázquez Morón JM; Pallarés Manrique H; Machancoses FH; Ramos Lora M; Ruiz Frutos C
    Rev Esp Enferm Dig; 2017 Feb; 109(2):130-136. PubMed ID: 28071062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
    Sydora MJ; Sydora BC; Fedorak RN
    J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12.
    Whitehead SJ; Ford C; Gama RM; Ali A; McKaig B; Waldron JL; Steed H; Brookes MJ
    J Clin Pathol; 2017 Dec; 70(12):1049-1056. PubMed ID: 28735301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of IBD disease activity by Interleukin-6 and serum amyloid A in relation with fecal calprotectin and endoscopic indices.
    Bahaa A; Elbaz T; Elmakhzangy H; Shehata M; Abd El-Kareem D; Gaber A; Hashem MB; El Raziky M
    Arab J Gastroenterol; 2024 Aug; 25(3):299-305. PubMed ID: 39039004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
    Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
    García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
    J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.
    Shimoyama T; Yamamoto T; Yoshiyama S; Nishikawa R; Umegae S
    Inflamm Bowel Dis; 2023 Sep; 29(9):1399-1408. PubMed ID: 36334015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Renzulli P; Seibold F
    Inflamm Bowel Dis; 2009 Dec; 15(12):1851-8. PubMed ID: 19462421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
    Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
    Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipopolysaccharide-binding protein in Crohn's disease patients: a promising noninvasive biomarker monitoring disease activity.
    Toris LD; Minsart CF; Husson CP; Franchimont DP; Liefferinckx CL
    Eur J Gastroenterol Hepatol; 2024 Sep; 36(9):1093-1100. PubMed ID: 38976551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the Liaison® Calprotectin kit with a well established point of care test (Quantum Blue - Bühlmann-Alere®) in terms of analytical performances and ability to detect relapses amongst a Crohn population in follow-up.
    Delefortrie Q; Schatt P; Grimmelprez A; Gohy P; Deltour D; Collard G; Vankerkhoven P
    Clin Biochem; 2016 Feb; 49(3):268-73. PubMed ID: 26506117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease.
    Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
    Eur J Clin Invest; 2016 Oct; 46(10):825-32. PubMed ID: 27438629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.
    Lobatón T; López-García A; Rodríguez-Moranta F; Ruiz A; Rodríguez L; Guardiola J
    J Crohns Colitis; 2013 Dec; 7(12):e641-51. PubMed ID: 23810085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis.
    Carlsen K; Riis LB; Elsberg H; Maagaard L; Thorkilgaard T; Sørbye SW; Jakobsen C; Wewer V; Florholmen J; Goll R; Munkholm P
    Scand J Gastroenterol; 2018; 53(7):825-830. PubMed ID: 29968483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fecal Human Neutrophil Peptide Levels Correlate with Intestinal Inflammation in Ulcerative Colitis.
    Kanmura S; Hamamoto H; Morinaga Y; Oda K; Fujita T; Arima S; Nasu Y; Sasaki F; Hashimoto S; Taguchi H; Setoyama H; Ido A
    Digestion; 2016; 93(4):300-8. PubMed ID: 27220673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound.
    Orlando A; Modesto I; Castiglione F; Scala L; Scimeca D; Rispo A; Teresi S; Mocciaro F; Criscuoli V; Marrone C; Platania P; De Falco T; Maisano S; Nicoli N; Cottone M
    Eur Rev Med Pharmacol Sci; 2006; 10(1):17-22. PubMed ID: 16494106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control.
    van Rheenen PF
    Inflamm Bowel Dis; 2012 Nov; 18(11):2018-25. PubMed ID: 22275341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy.
    Bar-Gil Shitrit A; Koslowsky B; Livovsky DM; Shitrit D; Paz K; Adar T; Adler SN; Goldin E
    Scand J Gastroenterol; 2017 Mar; 52(3):328-333. PubMed ID: 27841040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.